<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016207</url>
  </required_header>
  <id_info>
    <org_study_id>IIR-DEU-002258</org_study_id>
    <nct_id>NCT04016207</nct_id>
  </id_info>
  <brief_title>Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin</brief_title>
  <official_title>Non-interventional Trial to Investigate the Change of Psychopathological Markers of Affective Dysregulation (AD) in Children With Attention Deficit Hyperactivity Disorder (ADHD) Treated by Guanfacin, a Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Dr. Veit Roessner and PD Dr. Robert Waltereit jointly lead and conduct the study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early onset, high prevalence and persistence, as well as developmental comorbidity make
      affective dysregulation (AD) in childhood one of the most psychosocially impairing and
      cost-intensive mental conditions. Despite continuous research, there is still a substantial
      need for optimization of individual treatment strategies in order to improve outcomes and to
      reduce subjective and economic burden. Here we want to study the change of psychopathological
      markers of affective dysregulation (AD) treatment of affective dysregulation (AD) in children
      with Attention Deficit Hyperactivity Disorder (ADHD) treated by Guanfacine. These children
      did not respond to methylphenidate treatment. The results will allow the generation of a
      hypothesis for a randomized clinical trial to investigate the efficacy and safety of
      Guanfacine for the treatment of AD in children.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DADYS-EF (Diagnostikum für Affektive Dysregulation, Eltern-Fragebogen)</measure>
    <time_frame>9 weeks</time_frame>
    <description>The DADYS is a German instrument to assess affective dysregulation. The Eltern-Fragebogen is the parents' version of the rating scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DADYS-KF (Diagnostikum für Affektive Dysregulation, Kinder-Fragebogen)</measure>
    <time_frame>9 weeks</time_frame>
    <description>The DADYS is a German instrument to assess affective dysregulation. The Kinder-Fragebogen is the childrens' version of the rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners3L</measure>
    <time_frame>9 weeks</time_frame>
    <description>The Conners 3rd Edition™ (Conners 3®) is a thorough assessment of attention-deficit/hyperactivity disorder (ADHD) and its most common comorbid problems and disorders in children and adolescents aged 6 to 18 years. It is a multi-informant assessment that takes into account home, social, and school settings, with rating forms for parents, teachers, and youth.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Affective Dysregulation</condition>
  <arm_group>
    <arm_group_label>Guanfacin regular treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>regular treatment</description>
    <arm_group_label>Guanfacin regular treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the diagnosis of ADHD, Age 6-17 years
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female patients (aged 6 to 17 years)

          -  clinical diagnosis of ADHD (F90.0) or comorbid ADHD and Oppositional defiant disorder
             (ODD) (F90.1)

          -  patients with ADHD who did not respond to stimulants

          -  DADYS is an instrument to assess AD and has a domain for disruptive behaviors.
             Inclusion criterion for the study is a score of at least moderate (middle) severity in
             the DADYS parents version this domain

          -  IQ must be at least 70

          -  Patients receiving or intended to receive Guanfacin

          -  Written informed consent by the custodian and the children

        Exclusion Criteria:

          -  unipolar depression, bipolar disorder, schizophrenia or any other psychotic disorder

          -  current substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veit Roessner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Technical University Dresden, Child and Adolescent Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Waltereit, MD</last_name>
    <phone>+493514582244</phone>
    <email>robert.waltereit@uniklinikum-dresden.de</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Robert Waltereit</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

